Shirley P. D'sa
Queen Square
London, ENG, United Kingdom
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 110 publications
Bortezomib in Patients Who Fail BTKi in Waldenström Macroglobulinaemia.
Journal: Hematology reports
Published: February 15, 2026
Acquired vitamin B6 deficiency in POEMS: a marker of disease activity and cause of neuropathy?
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: December 21, 2025
Avoiding serious treatment-emergent adverse events in Waldenström macroglobulinemia patients.
Journal: Expert review of hematology
Published: December 16, 2025
Zanubrutinib in AL Amyloidosis Associated With Waldenström Macroglobulinemia and Other B-Cell Non-Hodgkin Lymphoma.
Journal: American journal of hematology
Published: November 01, 2025
Clinical features and treatment outcomes of POEMS-associated Castleman disease.
Journal: British journal of haematology
Published: October 01, 2025
Front-line systemic treatment outcomes in POEMS syndrome.
Journal: British journal of haematology
Published: September 27, 2025
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up.
Journal: Blood advances
Published: September 17, 2025
Patient Perception of the Relevance of Quality-of-Life Questionnaires in Waldenström Macroglobulinaemia: An International Survey.
Journal: Cancers
Published: August 18, 2025
POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia.
Journal: Blood advances
Published: July 14, 2025
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia.
Journal: Blood advances
Published: July 14, 2025
Last Updated: 09/26/2026